Abstract: There is provided an invention relating to compositions and therapeutic uses of atomic quantum clusters (AQCs), in particular compositions consisting essentially of AQCs comprising 5 zero-valent transition metal atoms for use in the treatment of a cell proliferative disorder.

Abstract: There is provided an invention relating to methods of purifying atomic quantum clusters, in particular those consisting of 3 or fewer zero-valent metal atoms. The invention also relates to compositions and uses of such compositions, for the treatment of cell proliferative disorders.

Abstract: The present invention relates to luminescent complexes comprising a charged transfer complex of metal atomic quantum clusters (AQCs) of at least two different sizes and a biotin-binding molecule, preferably streptavidin, and the use thereof for the detection of biotinylated compounds. The invention also relates to the use of conjugates comprising a charged transfer complex of AQCs and a biomolecule and the use thereof for the detection of binding partners of the biomolecule in a sample based on the luminescent properties of the AQCs nanosystems.

Abstract: Methods for diagnosing follicular thyroid cancer, providing a prognosis for follicular thyroid cancer, and monitoring treatment of follicular thyroid cancer, using biomarkers that are differentially expressed in follicular thyroid cancer are provided.

Abstract: The present invention relates to conjugates of formula (I) having colloidal stability in a medium, wherein NP is a gold, silver or platinum nanoparticle; L is a linker selected from the group consisting of formula (II), formula (III), and a stereoisomer of any of the formulas (II) and (III), which is attached to the nanoparticle NP through sulfur atoms; wherein the meanings of X, n, p, Y and s are further specified in the description; and A is a platinum (II) biradical selected from the group consisting of formula (IV), formula (V) and formula (VI) including any of the stereoisomers of all of them, wherein the biradical is optionally in the form of a salt and is attached to the linker L through the single bonded oxygen atoms of the carboxyl groups. It also relates to a process for the preparation of the conjugates of formula (I) and to pharmaceutical compositions containing them. The conjugates of the invention are used for the treatment of cancer.